Travere Therapeutics Inc
Company Profile
Business description
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Contact
3611 Valley Centre Drive
Suite 300
San DiegoCA92130
USAT: +1 888 969-7879
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
497
Stocks News & Analysis
stocks
This ASX supermarkets business is now underperforming its largest competitor
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.30 | 31.20 | 0.35% |
| CAC 40 | 8,013.44 | 37.32 | 0.47% |
| DAX 40 | 24,184.38 | 193.11 | 0.80% |
| Dow JONES (US) | 48,941.90 | 557.37 | -1.13% |
| FTSE 100 | 10,270.71 | 93.22 | -0.90% |
| HKSE | 25,898.61 | 197.27 | -0.76% |
| NASDAQ | 25,067.80 | 46.64 | -0.19% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,035.70 | 61.98 | -0.47% |
| S&P 500 | 7,200.75 | 29.37 | -0.41% |
| S&P/ASX 200 | 8,680.50 | 38.80 | 0.45% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |